Abstract
Introduction: In accordance to international classification Tioureidoiminomethylpyridinium perchlorate (Perchlozon) belongs to thioacetazone group [D.Tomas, 2014].
Objective: to confirm data on safety and efficacy of Tioureidoiminomethylpyridinium perchlorate (Pch) in treatment of multidrug resistant (MDR) lung tuberculosis.
Materials and methods: in vitro Pch demonstrated significant inhibiting effect on viability of drug-resistant mycobacteria strains of TB. Wherein MIC of the substance varied from 0.78 to 6.25 ug/ml. In the reported clinical study, which was performed in 2013-2014, 49 patients with MDR lung tuberculosis were enrolled. The patients were divided in two groups: Group 1 (main) 25 patients were administered Pch in addition to 6 other anti-tuberculosis drugs; in Group II (comparison) 24 patients received 6 anti-tuberculosis drugs. Duration of treatment in both groups was 6 months. After that in both groups 5 drugs in 6 mohth. Statistical analysis was peformed using SPSS 16.0.
Results and their discussion: In Group 1 the most common adverse drug reactions were endocrine disorders (18.4% (9) vs (0), p<0,01) and fever (8.2% (4) vs (0), p<0,05) – which were not observed in Group 2. Other adverse drug reactions were recorded in equal measures in both groups. Efficacy of treatment (which was assessed by cessation of bacterial excretion in sputum) was higher in Group 1 vs. Group 2 - both after 3 months (68.0 % (17) vs 37.5% (9) and after 6 months (80.0% (20) vs 62.5% (15) of study treatment start, after 12 month (88.0% (22) vs 66.7% (16).
Conclusion: Efficacy of treatment with Pch was 88.0% in complex with other anti-tuberculosis drugs.
- Copyright ©ERS 2015
